Medicare

Aledade Expands Value-Based Care Support Nationwide for 2024

Retrieved on: 
Thursday, March 14, 2024
Acos, Community, MSSP, Patient, Medicare, Medicare Advantage, Medicaid, Playbook, Nursing

Bethesda, MD, March 14, 2024 (GLOBE NEWSWIRE) -- Aledade added more than 400 new primary care practices, clinics and community health centers, and more than 60 health plan contracts, to its network for 2024, further expanding its reach as the largest and most successful enabler of physician-led value-based care in the United States.

Key Points: 
  • Bethesda, MD, March 14, 2024 (GLOBE NEWSWIRE) -- Aledade added more than 400 new primary care practices, clinics and community health centers, and more than 60 health plan contracts, to its network for 2024, further expanding its reach as the largest and most successful enabler of physician-led value-based care in the United States.
  • Aledade partners with more than 20,000 primary care providers and clinicians in 45 states and the District of Columbia.
  • Among the top 10 MSSP ACOs in the United States, five are Aledade ACOs.
  • Aledade ACOs continue to outperform other tenured ACOs in both quality scores and Medicare shared savings.

Noridian Continues To Support Providers and Suppliers Amid Change Healthcare Cyber Security Incident

Retrieved on: 
Thursday, March 14, 2024
American Samoa, DME, Change Healthcare, Senior, Medicare, CMS, Health insurance

FARGO, N.D., March 14, 2024 (GLOBE NEWSWIRE) -- Noridian Healthcare Solutions, LLC (Noridian) , a leader in developing solutions for federal, state and commercial health care programs, is providing billing and claims processing support to providers impacted by the repercussions of the recent Change Healthcare cyber security incident.

Key Points: 
  • FARGO, N.D., March 14, 2024 (GLOBE NEWSWIRE) -- Noridian Healthcare Solutions, LLC (Noridian) , a leader in developing solutions for federal, state and commercial health care programs, is providing billing and claims processing support to providers impacted by the repercussions of the recent Change Healthcare cyber security incident.
  • In collaboration with the Centers for Medicare & Medicaid Services (CMS), Noridian is offering multiple options for navigating billing challenges, including electronic workarounds.
  • Additionally, Noridian streamlines the process for requesting Accelerated and Advance Payments to provide financial relief to impacted providers.
  • Through collaborative efforts with the CMS and other stakeholders, Noridian is working to facilitate options to resolve the ongoing challenges posed by Change Healthcare’s cyber security incident.

GoHealth Reports Fourth Quarter and Fiscal 2023 Results

Retrieved on: 
Thursday, March 14, 2024
CFO, Trust, GoHealth, Sri Jayawardenepura Kotte, Table, Adjustment, GAAP, Medicare, Video game

CHICAGO, March 14, 2024 (GLOBE NEWSWIRE) -- GoHealth, Inc. (NASDAQ: GOCO) (“GoHealth” or the “Company”), a leading health insurance marketplace and Medicare-focused digital health company, today announced unaudited financial results for the fourth quarter and year ended December 31, 2023.

Key Points: 
  • CHICAGO, March 14, 2024 (GLOBE NEWSWIRE) -- GoHealth, Inc. (NASDAQ: GOCO) (“GoHealth” or the “Company”), a leading health insurance marketplace and Medicare-focused digital health company, today announced unaudited financial results for the fourth quarter and year ended December 31, 2023.
  • The percentage of revenue earned from non-agency sales in the fourth quarter was 60% of Medicare revenue, compared to 26% in 2022.
  • Fourth quarter 2023 net revenues were $276.7 million, compared to $69.4 million in the prior year period.
  • Fourth quarter 2023 net loss was $2.3 million and Adjusted EBITDA1 was $57.0 million, improvements of 98.5% and 160.1%, respectively, compared to the prior year period.

FINAL DEADLINE REMINDER FOR CMI INVESTORS: Kessler Topaz Meltzer & Check, LLP Announces Final Lead Plaintiff Deadline in Securities Class Action Lawsuit Filed Against Cummins Inc. (CMI)

Retrieved on: 
Thursday, March 14, 2024
Certification, IRS, District court, Lead, CFTC, LLP, COPY, News, RAM, DOJ, CMI, EPA, Fraud, Medicare, Court, Person, Pharmaceutical industry

The action charges Cummins with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company’s business, operations, and prospects.

Key Points: 
  • The action charges Cummins with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company’s business, operations, and prospects.
  • As a result of Cummins’ s materially misleading statements and omissions to the public, Cummins’ s investors have suffered significant losses.
  • Kessler Topaz Meltzer & Check, LLP encourages Cummins investors who have suffered significant losses to contact the firm directly to acquire more information.
  • The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel.

Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update

Retrieved on: 
Wednesday, March 13, 2024
HCC, Research, PIN, Conference call, Congress, Relative value unit, Conference, Head, Exercise, NSCLC, Risk, Patient, CHRS, Otorhinolaryngology, Biomarker, Sale, Acquisition, NCCN, NPC, Ophthalmology, IL-27, IND, Bevacizumab, OPSCC, Investigational New Drug, Investment, ESMO, GAAP, Workforce, Medicare, FDA, COGS, Total, Development, Pharmaceutical industry

UDENYCA net product sales increased 10% in the fourth quarter 2023 to $36.2 million compared to $33.0 million in the third quarter.

Key Points: 
  • UDENYCA net product sales increased 10% in the fourth quarter 2023 to $36.2 million compared to $33.0 million in the third quarter.
  • Since commercial launch in May 2023, more than 727 accounts have ordered the Autoinjector presentation.
  • “Throughout 2023, Coherus demonstrated significant progress in transforming the Company’s business model and product portfolio for long-term sustainable growth,” said Denny Lanfear, Coherus’ Chairman and Chief Executive Officer.
  • Coherus is introducing a guidance range of combined 2024 R&D and SG&A expenses from $250 to $265 million.

Clover Health Reports Fourth Quarter and Full Year 2023 Financial Results; Delivers Continued Momentum in Financial Performance and Provides Full-Year 2024 Guidance

Retrieved on: 
Tuesday, March 12, 2024
Insurance, PPO, Clover, Medicare, MCR, Economics, Clover Health

FRANKLIN, Tenn., March 12, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ: CLOV) ("Clover," "Clover Health" or the "Company"), a managed care company focused on physician enablement, today reported financial results for the fourth quarter and full year 2023. Management will host a conference call today at 5:00 p.m. ET to discuss its operating results and other business highlights.

Key Points: 
  • FRANKLIN, Tenn., March 12, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ: CLOV) ("Clover," "Clover Health" or the "Company"), a managed care company focused on physician enablement, today reported financial results for the fourth quarter and full year 2023.
  • For the fourth quarter 2023, the Company reported revenue of $510.3 million and net loss of $70.5 million, with full-year revenue of $2,033.7 million and net loss of $213.4 million.
  • Insurance revenue during the fourth quarter grew by 12% to $303.1 million, and grew by 14% to $1,235.8 million for full-year 2023.
  • Insurance MCR also meaningfully improved to 82.4% in the fourth quarter and 81.2% for full-year 2023, as compared to 92.4% in the fourth quarter 2022 and 91.8% for full-year 2022.

BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study

Retrieved on: 
Tuesday, March 12, 2024
BCDA, Patient, Mortality, Quality of life, Therapy, LVAD, Medicare, FDA, CMS, Arrest, Heart failure, Pharmaceutical industry

CMS has reviewed the CardiAMP Heart Failure II Trial and approved the investigational product, related and routine items and services for purposes of Medicare coverage.

Key Points: 
  • CMS has reviewed the CardiAMP Heart Failure II Trial and approved the investigational product, related and routine items and services for purposes of Medicare coverage.
  • The CardiAMP Heart Failure II Trial is FDA approved to enroll up to 250 patients at up to 40 clinical centers.
  • “We are pleased that CMS has provided coverage support for the confirmatory CardiAMP Heart Failure II study.” said Peter Altman, PhD., BioCardia’s President and Chief Executive Officer.
  • “To my knowledge, no therapy has been proven to reduce mortality in these patients, and CardiAMP Heart Failure II has great potential to achieve this outcome by confirming our CardiAMP Heart Failure Trial results.”

CorMedix Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, March 12, 2024
Kidney, Drug, Patient, ESRD, Prospective payment system, NDA, Investment, Annual report, Medicare, FDA, CMS, Hand

CorMedix’s TDAPA application remains under review, and CMS has confirmed that it is working toward a July 1st effective implementation for TDAPA.

Key Points: 
  • CorMedix’s TDAPA application remains under review, and CMS has confirmed that it is working toward a July 1st effective implementation for TDAPA.
  • Pending a timely implementation of TDAPA, CorMedix intends to launch in the outpatient setting in July 2024.
  • Operating expenses during the fourth quarter of 2023 were $15.7 million, compared with $8.4 million in the fourth quarter of 2022, an increase of approximately $7.3 million.
  • The management team of CorMedix will host a conference call and webcast today, March 12, 2023, at 8:30 AM Eastern Time, to discuss recent corporate developments and financial results.

RetireeFirst Achieves HITRUST Risk-Based, 2-year Certification Demonstrating the Highest Level of Information Protection Assurance Alongside Executive Team Expansion, Reinforcing Commitment to Group Plan Sponsors and Retirees

Retrieved on: 
Tuesday, March 12, 2024
Ketan, FSA, CIO, Consultant, Health, Certification, Organization, Pressure, Growth, Face, EVP, CFO, Box, Stevie Awards, HITRUST, Risk, Salesforce, UnitedHealth Group, Sale, Commercial, Public sector, Trade union, Senior, Advocacy, CHRO, HRA, HSA, Medicare, Privacy, Customer service, Management

This achievement places RetireeFirst in an elite group of organizations worldwide that have earned this certification.

Key Points: 
  • This achievement places RetireeFirst in an elite group of organizations worldwide that have earned this certification.
  • “Organizations like ours are continually under pressure to address current and emerging threats and meet complex compliance, information protection, and privacy requirements.
  • RetireeFirst has a proven track record of excellence, having received the first HITRUST certification in 2019 and maintaining continuous certification since then,” said Mike Yoo, CIO at RetireeFirst .
  • The strategic hires further advance the company’s ongoing commitment to group plan sponsors and their retirees, and bring decades of combined industry experience and expertise to RetireeFirst.

Mdxhealth Adds Hereditary Prostate Cancer Genetic Test to Prostate Cancer Offering

Retrieved on: 
Tuesday, March 12, 2024
Diagnosis, Growth, Prostate cancer, Patient, Research, NCCN, Death, National Comprehensive Cancer Network, Insurance, Medicare

IRVINE, CA, and HERSTAL, BELGIUM – March 12, 2024 ( GlobeNewswire ) – MDxHealth SA (NASDAQ: MDXH) (the “Company” or “mdxhealth”), a commercial-stage precision diagnostic company, announces the introduction of a non-invasive genetic prostate cancer test through its urology sales channel.

Key Points: 
  • IRVINE, CA, and HERSTAL, BELGIUM – March 12, 2024 ( GlobeNewswire ) – MDxHealth SA (NASDAQ: MDXH) (the “Company” or “mdxhealth”), a commercial-stage precision diagnostic company, announces the introduction of a non-invasive genetic prostate cancer test through its urology sales channel.
  • With a simple saliva sample, the new comprehensive hereditary prostate cancer test offering provides insights into a patient’s risk of developing cancer, disease progression, and response to prostate cancer therapies.
  • Germline testing of prostate cancer patients is recommended in the National Comprehensive Cancer Network (NCCN) guidelines and is covered by Medicare and many commercial insurance plans, for eligible patients.
  • Decades of research indicate that prostate cancer has a strong genetic component with implications to ancestry.